IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.086
AS - Asia 13.522
EU - Europa 12.125
SA - Sud America 3.208
Continente sconosciuto - Info sul continente non disponibili 355
AF - Africa 344
OC - Oceania 29
Totale 54.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.865
SG - Singapore 4.717
IT - Italia 3.730
CN - Cina 3.302
RU - Federazione Russa 3.206
BR - Brasile 2.508
VN - Vietnam 1.926
GB - Regno Unito 1.407
BD - Bangladesh 1.049
HK - Hong Kong 949
DE - Germania 829
CA - Canada 800
FR - Francia 505
UA - Ucraina 471
SE - Svezia 383
FI - Finlandia 336
IN - India 327
IE - Irlanda 268
AR - Argentina 249
MX - Messico 248
NL - Olanda 206
TR - Turchia 187
PL - Polonia 183
ID - Indonesia 170
IQ - Iraq 137
ES - Italia 134
EC - Ecuador 126
ZA - Sudafrica 126
DK - Danimarca 123
JP - Giappone 119
IL - Israele 117
PK - Pakistan 99
CO - Colombia 87
AT - Austria 84
VE - Venezuela 62
UZ - Uzbekistan 61
MA - Marocco 57
AE - Emirati Arabi Uniti 54
LT - Lituania 48
PY - Paraguay 47
CL - Cile 44
PE - Perù 36
SA - Arabia Saudita 36
CR - Costa Rica 35
PH - Filippine 34
EG - Egitto 31
MY - Malesia 31
KE - Kenya 29
TN - Tunisia 29
CH - Svizzera 27
UY - Uruguay 23
AZ - Azerbaigian 22
DZ - Algeria 22
EU - Europa 21
HN - Honduras 21
BE - Belgio 20
BO - Bolivia 20
JO - Giordania 20
NP - Nepal 20
AU - Australia 18
JM - Giamaica 18
GT - Guatemala 17
KZ - Kazakistan 15
RO - Romania 15
AL - Albania 14
DO - Repubblica Dominicana 14
OM - Oman 13
TH - Thailandia 13
TW - Taiwan 12
CZ - Repubblica Ceca 11
NI - Nicaragua 11
SK - Slovacchia (Repubblica Slovacca) 11
AM - Armenia 10
GR - Grecia 10
HU - Ungheria 10
IR - Iran 10
PA - Panama 10
PT - Portogallo 9
BB - Barbados 8
BY - Bielorussia 8
KW - Kuwait 8
LB - Libano 8
MC - Monaco 8
NZ - Nuova Zelanda 8
PS - Palestinian Territory 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
MD - Moldavia 7
PR - Porto Rico 7
SN - Senegal 7
SV - El Salvador 7
BH - Bahrain 6
CG - Congo 6
ET - Etiopia 6
GE - Georgia 6
HR - Croazia 6
KR - Corea 6
LV - Lettonia 6
MK - Macedonia 6
QA - Qatar 6
Totale 54.217
Salva come PNG Salva come JPEG
Città #
Dallas 4.547
Singapore 2.470
Ashburn 1.650
San Jose 1.622
Chicago 1.317
Beijing 1.273
Los Angeles 1.126
Hong Kong 880
Council Bluffs 691
Ho Chi Minh City 614
Moscow 588
Salt Lake City 557
Milan 542
Southend 540
New York 519
Buffalo 462
Chandler 453
Fairfield 416
Hanoi 380
Houston 350
Rome 337
Woodbridge 334
San Mateo 332
Santa Clara 319
Tampa 314
Wilmington 290
Seattle 281
The Dalles 277
São Paulo 264
Dublin 258
Elk Grove Village 251
Ann Arbor 243
Cambridge 242
Falls Church 232
Lauterbourg 231
Hefei 221
Boardman 218
Helsinki 208
Ottawa 198
Jacksonville 194
Dearborn 162
Pisa 160
Beauharnois 156
Portsmouth 156
Warsaw 155
Orem 151
Phoenix 151
Montreal 150
Munich 142
Stevenage 142
Florence 135
Sterling 123
Brooklyn 121
Mexico City 121
Frankfurt am Main 119
Dong Ket 117
Lancaster 117
London 113
Lawrence 107
Tel Aviv 104
Toronto 102
Miami 101
Tokyo 101
Denver 100
Atlanta 95
Poplar 93
Amsterdam 92
Istanbul 90
Chennai 87
Rio de Janeiro 87
Johannesburg 84
Naples 83
Stockholm 81
Da Nang 78
Nuremberg 78
Columbus 73
Dulles 72
Bologna 68
Turin 68
Detroit 60
Haiphong 59
Figino 58
Belo Horizonte 57
Manchester 57
San Diego 56
Tashkent 56
Boston 53
Lappeenranta 53
Palermo 53
Washington 53
Kansas City 51
Turku 48
Brasília 46
Genoa 46
San Francisco 45
Baghdad 44
Charlotte 44
Quito 44
Curitiba 43
Querétaro 43
Totale 31.645
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.851
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.711
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.585
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 743
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 702
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 625
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 470
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 421
A simple echocardiographic score to rule out cardiac amyloidosis 396
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 387
A simple echocardiographic score to rule out cardiac amyloidosis 382
The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians 376
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 337
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 337
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 334
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 323
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 321
Adrenergic activation in heart failure: blockade or rebalance? 317
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 314
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 314
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 310
Eligibility for vericiguat in a real‐world, contemporary heart failure population 310
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 308
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 306
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 305
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 304
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 303
[Ten perspectives for research and innovation in cardiac amyloidosis] 302
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 301
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 300
Screening the health status of people working in a university 297
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 296
How to take arms against central apneas in heart failure 291
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 289
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 286
Sex-related differences in chronic heart failure 286
RNA-targeting and gene editing therapies for transthyretin amyloidosis 284
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 284
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 281
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 280
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 279
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 278
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 277
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 275
Cardiac light-chain deposition disease relapsing in the transplanted heart 274
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 272
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 271
Cardiac magnetic resonance findings and prognosis in type 1 myotonic dystrophy 270
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 269
Atrial amyloidosis: mechanisms and clinical manifestations 269
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 267
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 266
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 266
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 265
Update sui biomarcatori nello scompenso cardiaco. 264
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 264
Valve disease in cardiac amyloidosis: an echocardiographic score 262
Disease features and management of cardiomyopathies in women 262
Biomarkers for the diagnosis and management of heart failure: New frontiers 261
null 258
Biomarkers for the diagnosis and management of heart failure 256
null 253
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 252
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 249
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 248
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 248
The search for efficient diagnostic and prognostic biomarkers of heart failure 246
Renin profiling predicts neurohormonal response to sacubitril/valsartan 246
Role of Imaging in Cardiomyopathies 245
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 244
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 243
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 243
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 243
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 243
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 241
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 240
Valvular heart disease in patients with cardiac amyloidosis 240
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 238
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 238
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 237
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 236
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 233
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 231
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 230
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 229
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 229
null 228
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 227
Prognostic value of plasma Renin activity in heart failure. 227
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 227
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 227
null 226
Cardiac amyloidosis: Innovations in diagnosis and treatment 225
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 225
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 224
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 224
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 223
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 222
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 221
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 221
Totale 32.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 260.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 260.046
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.474 0 0 80 198 75 69 202 338 142 199 36 135
2022/20231.348 110 112 62 143 166 178 36 120 253 30 83 55
2023/20241.338 76 36 239 102 73 120 105 65 51 75 55 341
2024/202513.757 112 134 492 202 421 496 1.194 2.132 818 1.995 3.124 2.637
2025/202629.429 1.464 4.071 3.936 3.830 2.783 1.795 2.691 1.329 1.783 1.903 2.013 1.831
2026/20272.106 769 909 428 0 0 0 0 0 0 0 0 0
Totale 54.669